CVE:TAK Takeda Pharmaceutical (TAK) Stock Price, News & Analysis → Forget Nvidia, buy this A.I. Stock Now (From InvestorPlace) (Ad) Free TAK Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume143,897 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Takeda Pharmaceutical alerts: Email Address Ad Gold Safe ExchangeThe “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! About Takeda Pharmaceutical Stock (CVE:TAK)The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company, with partial American and British roots. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue.Read More Ad Gold Safe ExchangeThe “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! TAK Stock News HeadlinesApril 15, 2024 | seekingalpha.comJazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay OffApril 12, 2024 | bizjournals.comViewpoint: To stay on top, Boston must lead pharma’s transformationApril 17, 2024 | Paradigm Press (Ad)Bitcoin Rockets To Record High But Buy THIS InsteadRecently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…April 11, 2024 | benzinga.comAssessing Johnson & Johnson's Performance Against Competitors In Pharmaceuticals IndustryApril 3, 2024 | stockhouse.comLigand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI(TM)March 30, 2024 | msn.comThis could be the worst year yet for dengue in the AmericasMarch 27, 2024 | finance.yahoo.comEphicacy Bolsters Leadership Team with Four New HiresMarch 27, 2024 | finanznachrichten.deTakeda Pharmaceuticals: Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAEApril 17, 2024 | Paradigm Press (Ad)Bitcoin Rockets To Record High But Buy THIS InsteadRecently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…March 20, 2024 | markets.businessinsider.comScilex, Takeda Settle Paragraph IV Patent Infringement Lawsuit - Quick FactsMarch 13, 2024 | markets.businessinsider.comTakeda: Mezagitamab Phase 2 Trial Shows Positive Results In Primary Immune ThrombocytopeniaMarch 13, 2024 | msn.comUniversity Of Strathclyde Invites Applications For MSc Advanced Pharmaceutical Manufacturing Course Starting September 2024February 28, 2024 | finance.yahoo.comTakeda Pharmaceutical Co Ltd (TKD.HM)February 28, 2024 | msn.comTakeda and Biological E partner to boost dengue vaccine production in IndiaFebruary 27, 2024 | finance.yahoo.comCholera Vaccines Market to Reach USD 167.3 Million by 2030, Fueled by a CAGR of 9.0% from 2030 | MarketDigitsFebruary 27, 2024 | sg.finance.yahoo.comTakeda Accelerates Access to its Dengue Vaccine Through 'Make in India' Manufacturing Partnership with Biological E.February 27, 2024 | markets.businessinsider.comTakeda Signs Manufacturing Partnership With India's Biological E. For Dengue Vaccine QDENGAFebruary 27, 2024 | news.yahoo.comJapan's Takeda partners with India's Biological E. to boost dengue vaccine productionFebruary 25, 2024 | finance.yahoo.comNasdaq DM Asia Health Care Larg (^NQDMASIA20LMGBP)February 23, 2024 | forbes.comA Decade Of Innovation: How This CEO Transformed A Global Pharma GiantFebruary 20, 2024 | investing.comTakeda Pharmaceutical Co Ltd ADR (TAK)February 16, 2024 | finance.yahoo.comLigand Pharmaceuticals Expands Senior Leadership Team with Two Key HiresFebruary 12, 2024 | msn.comFDA Approves Takeda's Eohilia As First Oral Treatment For Inflammed EsophagusFebruary 12, 2024 | markets.businessinsider.comCentessa Pharmaceuticals: Buy Rating Backed by Strong Pipeline and Positive Drug DataFebruary 12, 2024 | markets.businessinsider.comTakeda Says FDA Approves EOHILIA To Treat Eosinophilic EsophagitisFebruary 12, 2024 | reuters.comTakeda's treatment becomes first oral therapy for esophageal condition in USJanuary 31, 2024 | msn.comEU okays Takeda's Hyqvia co-formulated with Halozyme's EnhanzeSee More Headlines Receive TAK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeCVE SectorManufacturing Industry Medicinal & Botanical Manufacturing Sub-IndustryN/A Current SymbolCVE:TAK CUSIPN/A CIKN/A Webwww.takugold.com Phone+1-604-6420115FaxN/AEmployees2,021Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesGilles DessureauInterim PresidentGregory Donald HayesInterim Chief Financial Officer, Corporate SecretaryPeter BuresDirectorDennis Gordon FentieDirectorJanet Lee-SheriffDirectorLori WaltonDirectorC.F. Wasser IIIDirectorMore ExecutivesKey CompetitorsHigh TideTSE:HITINovus EnergyCVE:NVS(EDW.V)CVE:EDW(FSN.V)CVE:FSN(FTE.V)CVE:FTEView All Competitors TAK Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Takeda Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Pure Gold Mining (PGM), Valhi (VHI) and Fission Uranium (FCUUF). How do I buy shares of Takeda Pharmaceutical? Shares of TAK stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (CVE:TAK) was last updated on 4/17/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Generational Wealth GameplanCrypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsThe “Perfect Storm” for GoldGold Safe ExchangeThe "Smart Money" Is Ready for May 1st Are You?Stansberry ResearchOptions trading has suddenly become more reliable.Eagle PublishingTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market AlertsThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Takeda Pharmaceutical Co Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.